Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis

ConclusionPatients receiving IV golimumab at 2 mg/kg had significantly greater improvements in the signs and symptoms of PsA and less radiographic progression through week 24. AEs were consistent with those seen with other anti–tumor necrosis factor agents.

Source: Arthritis and Rheumatism - October 27, 2017 Category: Rheumatology Authors: Arthur Kavanaugh, M. Elaine Husni, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu, Elizabeth C. Hsia Tags: Original Article Source Type: research